In this context, cohort studies in which the second-generation tau PET radiotracers [18F]PI-2620 and [18F]PM-PBB3 were used differentiated patients with PSP and CBS from healthy controls and disease controls [12, 39, 49]. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.